CBR-470-1

Key Product Details

Product Description

CBR-470-1 is a phosphoglycerate kinase 1 (PGK1) inhibitor. CBR-470-1 promotes accumulation of the reactive metabolites methylglyoxal (MGO) resulting in KEAP1 modification and dimerization, which in turn leads to activation of the Nrf2 transcriptional program. CBR-470-1 protects SH-SY5Y neuroblastoma cells from MPP⁺-induced cytotoxicity via the Keap1-Nrf2 cascade.

Product Specifications for CBR-470-1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CBR-470-1

The following data is based on the product molecular weight 365.89.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.73 mL	13.67 mL	27.33 mL
5 mM	0.55 mL	2.73 mL	5.47 mL
10 mM	0.27 mL	1.37 mL	2.73 mL
50 mM	0.05 mL	0.27 mL	0.55 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Zheng PGK1 inhibitor CBR-470-1 protects neuronal cells from MPP+. Aging (Albany NY) 2020 PMID: 32649311
• Bollong A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature 2018 PMID: 30323285

Product Documents for CBR-470-1